Orlistat: its current status as an anti-obesity drug.
A.B.Ballinger@mds.qmw.ac.uk. Orlistat is a non-centrally acting anti-obesity agent that acts locally in the gastrointestinal tract to inhibit lipase, ...
http://www.ncbi.nlm.nih.gov/pubmed/12007529...
|
Leukemia - Targeting lipid metabolism by the lipoprotein lipase ...
M of orlistat was observed, while no apoptosis was induced in healthy peripheral .... The same distance measure was used in multidimensional scaling (MDS). ...
http://www.nature.com/leu/journal/v22/n3/full/2405058a.html...
|
Orlistat in the treatment of obesity.
A.B.Ballinger@mds.qmw.ac.uk. Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. ...
http://www.ncbi.nlm.nih.gov/pubmed/11249520...
|
MDS Pharma Services - MDSPS In NEWS
MDS Pharma Services President Dave Spaight was quoted in the December 8, 2008 article .... The original report, "Pharmacodynamic Equivalence of Two Orlistat
...
http://www.mdsps.com/News/MDSPS_in_news/In_News2008.aspx...
|
Pharmacodynamic equivalence of two orlistat capsule formulations ...
MDS Pharma Services, St.-Laurent (Montréal), Québec, QC, Canada. OBJECTIVE: Orlistat is a reversible lipase inhibitor for obesity management. Orlistat ...
http://www.ncbi.nlm.nih.gov/pubmed/18541129...
|
FDA Issues Early Communication Regarding Deferasirox Safety in MDS
28 Sep 2009 ... "Many [patients with MDS] are over age 60 and the adverse events are ... FDA to Investigate Liver-Related Adverse Events Seen With Orlistat ...
http://www.medscape.com/viewarticle/709579...
|
Mycobacterium tuberculosis Rv3802c Encodes a Phospholipase ...
Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. ..... U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2625445/...
|
Barriers to Weight Loss Counseling: Results
The majority of the populations studied were physicians (MDs). .... Keller C. Review: dietary plus pharmacological intervention (orlistat or sibutramine) ...
http://www.medscape.com/viewarticle/705663_3...
|
BioSpace offers Pharmaceutical, Biotechnology and Healthcare ...
Weight-Loss Drug Orlistat May Not Inspire Diet Change, Ulleval University ... Survival Benefit in Higher-Risk MDS Extends to AML Patients 12/9/2008 More. ...
http://www.biospace.com/news_subject_all_results.aspx?Catago...
|
Barriers to Weight Loss Counseling: Recommendations
In comparison, a study of primary care MDs found an average of 10.1 minutes ... Keller C. Review: dietary plus pharmacological intervention (orlistat or ...
http://www.medscape.com/viewarticle/705663_5...
|
